The Evolving Role of Pathology to Guide Precision Care Decisions in Myelodysplastic Syndromes

Join us in New Orleans for a live, interactive CME- and MOC-certified symposium. A panel of expert hematopathologists will discuss key elements in the diagnostic work-up for MDS with a focus on ring sideroblasts and SF3B1 mutations. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Provided by Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, in accordance with CAP’s COVID-19 protocols, all in-person learners will be asked to wear a mask and present their CAP 2022 conference badge -OR- proof of vaccination* AND government-issued ID to gain admittance to The Evolving Role of Pathology to Guide Precision Care Decisions in Myelodysplastic Syndromes event.

For more information on CAP’s vaccination and mask requirements, please visit: CAP’s website

*If you do not have your vaccination record card, find other ways to verify you have been vaccinated.

This is not an official event of CAP22 and is not sponsored, endorsed, or accredited by the CAP or any of the co-sponsoring organizations of CAP22.

 

Agenda

  • Welcome and Introduction
  • MDS Classification Schemes and Pathology Workup
  • The Pathologists’ Assessment of Ring Sideroblasts and SF3B1 Mutations
  • “Tying It All Together” Case Discussion: Evidence-Based Treatment Strategies for MDS-RS and MDS/MPN-RS-T
  • Key Takeaways
  • Audience Question and Answer

Events

Date / Time
Event Details

Faculty

Faculty
Tal Oren, MD, PhD

Hematopathologist
Stamford Hospital
Stamford, Connecticut

Faculty
Alexa J. Siddon, MD

Associate Professor, Laboratory Medicine and Pathology
Hematopathology Fellowship Director
Yale School of Medicine
New Haven, Connecticut

Faculty
Cecilia Yeung, MD

Associate Professor
Clinical Research Division
Fred Hutch Cancer Center
University of Washington
Seattle, Washington

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to accurately diagnose and provide evidence-based treatment strategies for patients with MDS-RS and MDS/MPN-RS-T.

Target Audience
This educational program is intended for pathologists, hematopathologists, hematologists, hematologists/oncologists, and other healthcare professionals involved in precision care of MDS.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Formulate an actionable diagnostic workup plan for MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis considering ring sideroblast quantification and evaluation, current guidelines, and clinical evidence
  • Ascertain the clinical rationale for SF3B1 testing combined with ring sideroblast assessment in the diagnosis of MDS, based on the currently available data, guidelines, and expert recommendations
  • Identify technologies available to pathologists that can be used to test for SF3B1 mutations
  • Integrate into practice adequate sampling and sampling types for the accurate diagnosis of MDS with ring sideroblasts and MDS/MPN with ring sideroblasts and thrombocytosis to guide treatment decisions

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.